

# Nicole A Doria-Rose

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5139173/nicole-a-doria-rose-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72  
papers

9,994  
citations

34  
h-index

78  
g-index

78  
ext. papers

13,823  
ext. citations

24.8  
avg, IF

5.59  
L-index

#	Paper	IF	Citations
72	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.. <i>New England Journal of Medicine</i> , <b>2022</b> ,	59.2	54
71	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.. <i>Cell Reports</i> , <b>2022</b> , 38, 110199	10.6	3
70	Defining the risk of SARS-CoV-2 variants on immune protection.. <i>Nature</i> , <b>2022</b> ,	50.4	7
69	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.. <i>Cell</i> , <b>2022</b> ,	56.2	22
68	Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants. <b>2022</b> ,		1
67	Protocol to identify and monitor key mutations of broadly neutralizing antibody lineages following sequential immunization of Ig-humanized mice.. <i>STAR Protocols</i> , <b>2022</b> , 3, 101180	1.4	
66	Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2.. <i>Advanced Science</i> , <b>2022</b> , e2200063	13.6	
65	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. <i>EClinicalMedicine</i> , <b>2022</b> , 101477	11.3	0
64	Binding and Neutralizing Antibody Responses to SARS-CoV-2 in Infants and Young Children Exceed Those in Adults. <b>2021</b> ,		1
63	Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. <b>2021</b> ,		46
62	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung.. <i>Cell</i> , <b>2021</b> ,	56.2	24
61	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , <b>2021</b> , 374, 1343-1353	33.3	32
60	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with anamnestic antibody response in the lower airway <b>2021</b> ,		4
59	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. <i>Cell Reports</i> , <b>2021</b> , 35, 108937	10.6	1
58	Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants <b>2021</b> ,		21
57	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2259-2261	59.2	298
56	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373,	33.3	80

55	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 80-82	59.2	392
54	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , <b>2021</b> , 371,	33.3	22
53	Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. <i>Immunity</i> , <b>2021</b> , 54, 324-339.e8	32.3	15
52	Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects <b>2021</b> ,		4
51	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. <i>Cell Reports</i> , <b>2021</b> , 36, 109353	10.6	41
50	Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman Primates <b>2021</b> ,		8
49	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373, 1372-1377	33.3	150
48	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. <i>Cell Host and Microbe</i> , <b>2020</b> , 27, 531-543.e6	23.4	8
47	Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen. <i>Scientific Reports</i> , <b>2020</b> , 10, 3032	4.9	24
46	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. <i>Cell Reports</i> , <b>2020</b> , 31, 107488	10.6	22
45	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 3299-3304	15.9	9
44	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 2427-2438	59.2	737
43	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , <b>2020</b> , 586, 567-571	50.4	594
42	An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1920-1931	59.2	1704
41	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1544-1555	59.2	612
40	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. <i>Cell Reports</i> , <b>2020</b> , 32, 107981	10.6	7
39	Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	9
38	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , <b>2019</b> , 50, 1513-1529.e9	32.3	53

37	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , <b>2019</b> , 14, e0215163	3.7	25
36	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , <b>2019</b> , 50, 677-691.e13	32.3	38
35	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007632	7.6	9
34	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , <b>2019</b> , 178, 567-584.e19	56.2	64
33	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	11
32	Overexpression of T-bet in HIV infection is associated with accumulation of B cells outside germinal centers and poor affinity maturation. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	30
31	Toll-like receptor 7-adapter complex modulates interferon- $\beta$ production in HIV-stimulated plasmacytoid dendritic cells. <i>PLoS ONE</i> , <b>2019</b> , 14, e0225806	3.7	2
30	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. <i>Structure</i> , <b>2019</b> , 27, 196-206.e6	5.2	48
29	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , <b>2019</b> , 25, 59-72.e8	23.4	56
28	Toll-like receptor 7-adapter complex modulates interferon- $\beta$ production in HIV-stimulated plasmacytoid dendritic cells <b>2019</b> , 14, e0225806		
27	Toll-like receptor 7-adapter complex modulates interferon- $\beta$ production in HIV-stimulated plasmacytoid dendritic cells <b>2019</b> , 14, e0225806		
26	Toll-like receptor 7-adapter complex modulates interferon- $\beta$ production in HIV-stimulated plasmacytoid dendritic cells <b>2019</b> , 14, e0225806		
25	Toll-like receptor 7-adapter complex modulates interferon- $\beta$ production in HIV-stimulated plasmacytoid dendritic cells <b>2019</b> , 14, e0225806		
24	Rational design of a trispesific antibody targeting the HIV-1 Env with elevated anti-viral activity. <i>Nature Communications</i> , <b>2018</b> , 9, 877	17.4	43
23	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. <i>Cell Reports</i> , <b>2018</b> , 22, 1798-1809	10.6	33
22	Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 217, 1530-1534	7	5
21	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , <b>2018</b> , 24, 857-867	50.5	169
20	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	61

19	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , <b>2017</b> , 19, 719-732	10.6	123
18	HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	12
17	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , <b>2017</b> , 358, 85-90	33.3	176
16	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	65
15	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2037-2050	59.2	276
14	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , <b>2016</b> , 23, 81-90	17.6	126
13	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , <b>2016</b> , 90, 76-91	6.6	151
12	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , <b>2016</b> , 352, 828-33	33.3	218
11	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding. <i>Journal of Virology</i> , <b>2016</b> , 90, 10574-10586	6.6	19
10	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , <b>2015</b> , 21, 1332-6	50.5	154
9	Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. <i>Journal of Virology</i> , <b>2015</b> , 90, 2740-55	6.6	45
8	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , <b>2014</b> , 509, 55-62	50.4	537
7	Isolation of human monoclonal antibodies from peripheral blood B cells. <i>Nature Protocols</i> , <b>2013</b> , 8, 1907-15	15.8	94
6	Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. <i>Science</i> , <b>2013</b> , 340, 751-6	33.3	172
5	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. <i>Nature</i> , <b>2012</b> , 491, 406-12	50.4	624
4	Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. <i>Journal of Virology</i> , <b>2010</b> , 84, 1631-6	6.6	258
3	Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. <i>Science</i> , <b>2010</b> , 329, 856-61	33.3	1327
2	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron		12

- 1 Structural survey of HIV-1-neutralizing antibodies targeting Env trimer delineates epitope categories and suggests vaccine templates

3